Merck KGaA to Become the First CTDMO Offering Fully Integrated mRNA Services
In a significant milestone for the pharmaceutical industry, Merck KGaA has established itself as the pioneer Contract Testing, Development, and
Read moreIn a significant milestone for the pharmaceutical industry, Merck KGaA has established itself as the pioneer Contract Testing, Development, and
Read moreThe Biosimilar Tyruko® has been approved for all indications of reference medicine, as the first and only biosimilar to treat
Read moreThe GERBU Adjuvant MTM is developed specifically for monoclonal antibody production and offers a high yield of IgG and fused
Read moreThe MANDARA Phase III trial marks the first head-to-head comparison of biologics in treating eosinophilic granulomatosis with polyangiitis (EGPA), putting
Read moreThe partnership with Samsung Bioepis Grants Novartis’ generic-drugs unit Sandoz exclusive commercialization rights for biosimilar SB17 Ustekinumab in Europe and
Read moreThe new Anti-mouse CD45 Antibody from HistoSure is specifically developed for superior results in IHC-P (FFPE) applications. Anti-Mouse CD45 Antibody
Read moreInflaRx N.V., a biopharmaceutical company in the clinical stage of developing anti-inflammatory therapeutics that target the complement system, has announced
Read moreGERBU’s Ready-to-use Immunoadjuvants are Economical and Animal Friendly A GERBU Biotechnik .pdf Brochure The unique GERBU Adjuvant PluS, Adjuvant S,
Read moreThe European Commission has authorised Sanofi and Regeneron’s Dupixent® (dupilumab) as the first and only therapeutic therapy for eosinophilic esophagitis.
Read moreEvusheld, a long-acting antibody (LAAB) combination from AstraZeneca, has received emergency use authorisation (EUA) by the FDA in the United
Read more